Cancer vaccine halves melanoma risk

A new experimental vaccine has been developed that reduces the risk of melanoma recurrence or death from the cancer by 49% over five years, representing significant progress in the treatment of this type of cancer. According to Dr. Hizkiyahu Emanuel, a former health policy advisor at the White House, this new therapy could enhance the effectiveness of cancer control strategies and change the future of treatment for skin cancer patients.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل